Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F144 - Autoimmune Blistering Diseases: What's New

Monday, February 19; 3:30 PM - 5:30 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Select the most appropriate treatments for patients with pemphigus and pemphigoid.
  • Know about current clinical trials in pemphigus and pemphigoid
  • Prompt the patient for information on relevant triggers for pemphigoid

Description

The session is directed towards physicians managing patients with autoimmune blistering diseases, particularly pemphigus and pemphigoid. It will cover the latest advances in management, including rituximab, Bruton tyrosine kinase inhibitor studies and IVIG for pemphigus. For pemphigoid it will review the latest understanding of the triggers for the disease and the newest evidence for treatment.

Disclosures

  • Caux, Frederic, PhD: LEO Laboratories Ltd (LEO Pharma) – I(Fees); Pierre Fabre Dermatologie – C(H); Principia Biopharma Inc – I(Fees); Roche Laboratories – I(Fees);
  • Fairley, Janet A., MD: Immune Pharmaceuticals – I(Grants/Research Funding);
  • Joly, Pascal, MD, PhD: Almirall – C(H); GlaxoSmithKline – C(H); Lilly ICOS LLC – C(H); Novartis Pharmaceuticals Corp. – C(H); Principia Biopharma Inc – C(H); Roche Laboratories – C(H); sanofi-aventis – C(H);
  • Murrell, Dedee F., MD: 3M Pharmaceuticals – C(Grants/Research Funding); Abbott Laboratories – A(H), SP(H); AbbVie – I(Grants/Research Funding); Actavis – Speaker/Faculty Education(H); Almirall – C(H); Amgen – I(Fees); Amicus Therapeutics – A(H); Anacor Pharmaceuticals, Inc. – I(Grants/Research Funding); Ascent Pharmaceuticals – SP(H); Castle Creek Pharmaceuticals – C(Fees); CSL – SP(Grants/Research Funding), SP(H); Delfin Technology – I(EQ); Eli Lilly and Company – A(H); Galderma Laboratories, L.P. – I(Grants/Research Funding), I(OB); Janssen-Ortho Inc. – O(Grants/Research Funding); Leo Pharma Inc – Speaker/Faculty Education(H); Medimmune – I(Grants/Research Funding); Merck Serono – I(Fees), I(Grants/Research Funding); Molynlycke – SP(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H), I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Pierre Fabre Dermo-Cosmétique US – SP(H); Principia Biopharma Inc – C(H); Roche Laboratories – A(H), I(Grants/Research Funding); Samumed, LLC – I(Grants/Research Funding); Schering-Plough Corporation – I(Grants/Research Funding), SP(OB); Shire – A(H), I(Grants/Research Funding); Stiefel a GSK company – SP(H); XOMA (US) LLC – I(Grants/Research Funding);
  • Tasanen, Kaisa, MD, PhD: no financial relationships exist with commercial interests.
Schedule
Monday, February 19
3:30 PM
Dr. Joly / RCT of rituximab for pemphigus
3:55 PM
Dr. Murrell / BTK inhibitors for pemphigus
4:15 PM
Dr. Caux / IVIG for pemphigus
4:35 PM
Dr. Murrell, Dr. Joly, and Dr. Caux / Questions on pemphigus
4:45 PM
Dr. Tasanen / Triggers for bullous pemphigoid
5:05 PM
Dr. Fairley / New Treatments for bullous pemphigoid
5:25 PM
Dr. Murrell, Dr. Fairley, and Dr. Tasanen / Questions on pemphigoid
Event Details
  • Date
    Monday, February 19
  • Time
    3:30 PM - 5:30 PM
  • Location
    Room 26A
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
  • Dedee F. Murrell, MD, FAAD
Speakers
  • Frederic Caux, PhD
  • Janet A. Fairley, MD, FAAD
  • Kaisa Tasanen, MD, PhD
  • Pascal Joly, MD, PhD